Hsc Research and Development Limited Partnership

Other

The Hospital for Sick Children

The Ontario Cancer Institute

Hsc Research Development Corporation

Neuraltus Pharmaceuticals, Inc.

Hospital for Sick Children Research and Development Limited Partnership

Hsc Research and Development Limited

Microcarb, Inc.

Hcs Research and Development

The Hospital for Sick Children Research and Development LP

Antex Biologics, Inc.

Clifford A Lingwood

Richard C Hill

Michael S McGrath

Arasteh Ari Azhir

Hannah Farkas-Himsley

Ruth Geva, Legal Representative

Murugesapillai Mylvaganam

Leorah Kroyanker, Legal Representative

Sara Arab

Aye-Aye Khine

Howard C Krivan

Bo Nilsson

Hannah Farkas-Himsley, Deceased

Magdy T Basta

Mohammed A Karmali

Leorah Kroyanker

Ruth Geva

The present invention provides a method of blocking endoplasmic reticulum associated degradation of functional but misfolded proteins.

Use of a holotoxin to reduce endoplasmic reticulum-associated degradation of misfolded proteins

The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.

Compositions and methods for treating lysosomal disorders

Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.

Verotoxin pharmaceutical compositions and medical treatments therewith

Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Methods of preparing and using the hybrid compounds are also provided.

Hybrid compositions for intracellular targeting

Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb ; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Mehtods of preapring and using the hybrid compounds are also provided.

An adhesin protein which binds specifically to phosphatidylethanolamine (PE), gangliotriaosylceramide (Gg,) and gangliotetraosylceramide (Gg,) has been isolated and purified from,. Also provided are immunogenic compositions and methods of protecting susceptible mammals from diseases caused by bacterial pathogens having the adhesin as a surface protein.

Haemophilus adhesin protein

Glycolipid mimics which include a rigid hydrophobic moiety are disclosed. Methods of using the glycolipid mimics are also disclosed.

Glycolipid mimics and methods of use thereof

An adhesin protein which binds specifically to phosphatidylethanolamine (PE), gangliotriaosylceramide (Gg.sub.3) and gangliotetraosylceramide (Gg.sub.4) has been isolated and purified from H. influenzae. Also provided are immunogenic compositions and methods of protecting susceptible mammals from diseases caused by bacterial pathogens having the adhesin as a surface protein.

Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1 and their pentameric subunit B, have been found to be useful in the treatment of mammalian neoplasia, particularly, brain cancer, ovarian cancer, breast cancer and skin cancer. Although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo. Use of a sensitizer, such as sodium butyrate, enhances the efficacy of verotoxins and their subunit B.

Methods for the in vitro and in vivo inhibition of microbial colonization are provided. The methods use host cell phospholipid molecules ('receptors') which bind microorganisms.

Growing community of inventors

Toronto, Canada

Clifford A Lingwood